Bio-Rad Laboratories, Inc. (BIO) Stock Price & Analysis
Bio-Rad Laboratories, Inc. (BIO) rose 2.01% to USD 297.17 as of June 10, 2026 at 00:55 UTC, according to Nexqual real-time market data.
BIO last closed at USD 291.31; the session ranged USD 290.47–297.92 on volume of 358,419 shares. Market capitalization is $7.95B, with a 52-week range of USD 222.8–343.12 (NYQ). Source: Nexqual, June 10, 2026 at 00:55 UTC.
Key Statistics (as of June 10, 2026 at 00:55 UTC)
| Price | USD 297.17 |
|---|---|
| Change | ▲ 2.01% (up) |
| Previous Close | USD 291.31 |
| Open | USD 294.3 |
| Day Range | USD 290.47 – 297.92 |
| 52-Week Range | USD 222.8 – 343.12 |
| Volume | 358,419 shares |
| Market Cap | $7.95B |
| Exchange | NYQ |
Technical Analysis (BIO)
Nexqual's technical model rates BIO "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:55 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.18 (neutral) |
| vs SMA50 | Above (USD 281.99) |
| MACD | 7.44 (positive) |
Analyst Ratings (BIO)
Wall Street analysts rate BIO "None" based on 5 analysts, with a mean price target of USD 297 (range USD 275–320), per Nexqual as of June 10, 2026 at 00:55 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 297 |
| High Target | USD 320 |
| Low Target | USD 275 |
| Buy / Hold / Sell | 1 / 4 / 0 |
Earnings (BIO)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.75 |
| Revenue Estimate | $623.99M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.89 vs est 1.99 ▼ miss |
| 2025-12-31 | USD 2.51 vs est 2.7 ▼ miss |
| 2025-09-30 | USD 2.26 vs est 1.93 ▲ beat |
| 2025-06-30 | USD 2.61 vs est 1.75 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financials & Fundamentals (BIO)
| Total Revenue | $2.59B |
|---|---|
| Revenue Growth (YoY) | +1.10% |
| Gross Margin | +52.01% |
| Operating Margin | +5.76% |
| Profit Margin | +6.52% |
| ROE | +2.50% |
| Debt / Equity | 20.12 |
| Current Ratio | 3.21 |
| Total Cash | $1.56B |
| Total Debt | $1.38B |
| Free Cash Flow | $229.76M |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financial Health Score (BIO)
Nexqual rates Bio-Rad Laboratories, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:55 UTC.
| Growth | Mixed — Revenue +0.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 6% |
| Balance Sheet | Strong — $1.56B cash vs $1.38B debt, net cash position |
| Cash Flow | Solid — FCF $230M, 9% margin |
| Efficiency | Weak — ROE 2%, ROA 1.8% |
Ownership (BIO)
| Insider Ownership | +16.34% |
|---|---|
| Institutional Ownership | +94.40% |
| Shares Outstanding | 21.70M |
| Float | 20.91M |
| Short % of Float | +0.00% |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Leadership (BIO)
Bio-Rad Laboratories, Inc. is led by Norman D. Schwartz (age 75), Chairman & CEO, per Nexqual as of June 10, 2026 at 00:55 UTC.
| Chairman & CEO | Norman D. Schwartz (age 75) |
|---|---|
| President & COO | Jonathan P. DiVincenzo (age 59) |
| Executive VP & CFO | Roop K. Lakkaraju (age 54) |
| Executive VP & President of Life Science Group | James J. Barry (age 47) |
| Executive Vice President of Global Commercial Operations | Rajat Mehta (age 46) |
Major Backers & Investors (BIO)
Notable institutional backers of Bio-Rad Laboratories, Inc. include First Eagle Investment Management, LLC, Ariel Investments, LLC, SmallCap World Fund Inc, according to Nexqual as of June 10, 2026 at 00:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 20.65% |
| Ariel Investments, LLC | 3.62% |
| SmallCap World Fund Inc | 3.48% |
| Earnest Partners LLC | 2.71% |
| Capital Group | 2.07% |
| Bank of America Corporation | 2.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.62% |
| BlackRock | 10.57% |
| Dimensional Fund Advisors | 5.02% |
| State Street | 2.58% |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
From Bio-Rad Laboratories, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
- It operates through two segments, Life Science and Clinical Diagnostics.
- The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications.
- This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
| WST | West Pharmaceutical Services, I | USD 334.66 | ▲ 6.41% |
| TFX | Teleflex Incorporated | USD 135.75 | ▲ 4.55% |
| COO | The Cooper Companies, Inc. | USD 68.62 | ▲ 1.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:55 UTC. This page is informational and not investment advice.